•
Mar 31, 2023
Delcath Q1 2023 Earnings Report
Delcath reported preliminary financial results for Q1 2023 and provided a business update.
Key Takeaways
Delcath Systems reported preliminary Q1 2023 revenue of $0.6 million, compared to $0.4 million in Q1 2022. The company had cash, cash equivalents, and restricted cash totaling $24.3 million as of March 31, 2023, compared to $11.8 million as of March 31, 2022. They are awaiting the FDA's decision on Hepzato Kit with a PDUFA date of August 14, 2023.
Received FDA acknowledgement of Class 2 NDA resubmission for Hepzato Kit with a PDUFA goal date of August 14, 2023.
Completed a private placement of up to $85 million in gross proceeds, including $25 million upfront.
Amended loan agreement to defer $4.3 million in principal payments.
Appointed John R. Sylvester as Chairman of the Board.